Makers of copycat versions of Novo Nordisk's (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...

Semaglutide — the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy — can expire. If ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for compounding pharmacies to make copies of Ozempic and Wegovy.

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...

Drug compounders have filed a lawsuit against the FDA for removing Novo Nordisk's Wegovy and Ozempic from its shortage list. This decision restricts compounders from selling cheaper versions, despite ...

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug ...

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...